KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Current Liabilities (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Total Current Liabilities readings, the most recent being $300.8 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 22.16% to $300.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.8 million, a 22.16% increase, with the full-year FY2025 number at $300.8 million, up 22.16% from a year prior.
  • Total Current Liabilities hit $300.8 million in Q4 2025 for Esperion Therapeutics, down from $359.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $359.0 million in Q3 2025 to a low of $73.4 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $122.4 million (2023), compared with a mean of $157.3 million.
  • Biggest five-year swings in Total Current Liabilities: decreased 22.02% in 2021 and later surged 116.45% in 2025.
  • Esperion Therapeutics' Total Current Liabilities stood at $73.4 million in 2021, then grew by 25.84% to $92.3 million in 2022, then skyrocketed by 69.24% to $156.2 million in 2023, then soared by 57.62% to $246.2 million in 2024, then increased by 22.16% to $300.8 million in 2025.
  • The last three reported values for Total Current Liabilities were $300.8 million (Q4 2025), $359.0 million (Q3 2025), and $298.8 million (Q2 2025) per Business Quant data.